SCHEMBL233979

SCHEMBL233979

CCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 1.00
▸ NR5A2 O00482 1/20 1.00
▸ NR5A1 Q13285 1/20 1.00
▸ MAPT P10636 3/20 0.88
▸ FABP3 P05413 1/20 0.78
▸ RECQL P46063 1/20 0.77
▸ ALDH1A1 P00352 1/20 0.68
▸ ADRA1D P25100 1/20 0.66
▸ PTAFR P25105 1/20 0.66
▸ HTR1D P28221 1/20 0.66
▸ HTR2C P28335 1/20 0.66
▸ ADRA1B P35368 1/20 0.66
▸ DRD3 P35462 1/20 0.66
▸ TMEM97 Q5BJF2 1/20 0.66
▸ LPAR3 Q9UBY5 3/20 0.63
▸ LPAR1 Q92633 2/20 0.63
▸ ENPP2 Q13822 1/20 0.63
▸ MAPK1 P28482 3/20 0.60
▸ MEN1 O00255 2/20 0.60
▸ GMNN O75496 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL235513 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
Colfosceril Palmitate SCHEMBL184776 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL234621 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL234757 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL22693933 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL17165029 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL237094 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL2135188 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL233582 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL235645 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1844 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130354-A1 SMART AUTONOMOUS TOWER SYSTEM FOR INSECT EXTERMINATION AND MONITORING TECSOIL AUTOMAÇÃO E SISTEMAS S.A. (BR) 2026-05-14 — — US claimed
WO-2026090590-A1 NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE Remedium Bio, Inc. (US) 2026-04-30 — — WO claimed
EP-4731258-A1 LIPID NANOPARTICLES CONTAINING DISULFIDE LIPIDS AND FORMULATIONS THEREOF Providence Therapeutics Holdings Inc. (CA) 2026-04-29 — — EP claimed
EP-4365572-B1 BIOLOGICAL SAMPLE ANALYSIS DEVICE SONY GROUP CORP (JP) 2026-04-22 — — EP claimed
EP-4302139-B1 SCINTIGRAPHIC MEASUREMENT DEVICE WITH EXTENDED AREA CONSIGLIO NAZIONALE RICERCHE (IT) 2026-02-18 — — EP claimed
EP-4305466-B1 SCINTIGRAPHIC DETECTION DEVICE WITH A HIGH DEGREE OF COMPACTNESS AND SIMPLIFIED ELECTRONICS CONSIGLIO NAZIONALE RICERCHE (IT) 2026-02-18 — — EP claimed
EP-4695401-A1 SYNTHETIC CIRCUITS AND USES THEREOF Strand Therapeutics Inc. (US) 2026-02-18 — — EP claimed
US-20260035486-A1 APOLIPOPROTEIN NANODISCS WITH TELODENDRIMER NNSA 2026-02-05 — — US claimed
US-20260000730-A1 SOMATOSTATIN RECEPTOR AGONIST FORMULATIONS CAMURUS AB (SE) 2026-01-01 — — US claimed
EP-4659817-A2 LIPOSOME COMPOSITION FOR USE IN PERITONEAL DIALYSIS Versantis AG (CH) 2025-12-10 — — EP claimed
WO-2010030730-A1 POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF ABBOTT LABORATORIES (US) 2010-03-18 — — WO claimed
US-20100063135-A1 POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF ABBOTT LABORATORIES (US) 2010-03-11 — — US claimed
US-20090285881-A1 CATIONIC LIPIDS AND USES THEREOF ABBOTT LABORATORIES (US) 2009-11-19 — — US claimed
WO-2009129385-A1 CATIONIC LIPIDS AND USES THEREOF ABBOTT LABORATORIES (US) 2009-10-22 — — WO claimed
WO-2009129395-A1 CATIONIC LIPIDS AND USES THEREOF ABBOTT LABORATORIES (US) 2009-10-22 — — WO claimed
US-20070014842-A1 Pharmaceutical liposomal compositions ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) 2007-01-18 — — US claimed
US-20070014841-A1 Pharmaceutical compositions ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) 2007-01-18 — — US claimed
EP-1536831-A2 PHARMACEUTICAL LIPOSOMAL COMPOSITIONS CONTAINING N. MENINGITIDIS DERIVED POLYPEPTIDES OR POLYNUCLEOTIDES ID Biomedical Corporation (CA) 2005-06-08 — — EP claimed
US-20040132652-A1 Pharmaceutical compositions SHIRE BIOCHEM INC. (CA) 2004-07-08 — — US claimed
WO-2004019976-A2 PHARMACEUTICAL LIPOSOMAL COMPOSITIONS CONTAINING N. MENINGITIDIS DERIVED POLYPEPTIDES OR POLYNUCLEOTIDES ID BIOMEDICAL CORPORATION (CA) 2004-03-11 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063135-A1 POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF LIPA, LIPG, LIPC SMN1; SMN2 2289/4885NR5A2 3037/4885NR5A1 1639/4885
US-20260035486-A1 APOLIPOPROTEIN NANODISCS WITH TELODENDRIMER CETP, LDLR, APOL1 SMN1; SMN2 3592/4885NR5A2 2874/4885NR5A1 4057/4885
US-20260000730-A1 SOMATOSTATIN RECEPTOR AGONIST FORMULATIONS SSTR1, SSTR3, SSTR5 SMN1; SMN2 2450/4885NR5A2 2104/4885NR5A1 928/4885
US-20070014842-A1 Pharmaceutical liposomal compositions NGLY1, PHOSPHO1, LPXN SMN1; SMN2 1933/4885NR5A2 2921/4885NR5A1 3363/4885
US-20090285881-A1 CATIONIC LIPIDS AND USES THEREOF LIPA, SGMS2, SGMS1 SMN1; SMN2 2586/4885NR5A2 3864/4885NR5A1 3780/4885
US-20260130354-A1 SMART AUTONOMOUS TOWER SYSTEM FOR INSECT EXTERMINATION AND MONITORING CUTA, WAPL, RALA SMN1; SMN2 3277/4885NR5A2 3723/4885NR5A1 3681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback